drugset / Trial / NCT07867626
Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)
Timeline
- Start
- 2026-09-30
- Primary completion
- 2028-06
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedazuridine | Small molecule | — | Oral |
| Subject | Decitabine | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |